Differences

This shows you the differences between two versions of the page.

--- covid-19_vaccines:lipid_nanoparticle [2022/03/03 00:50]
liam [Intellectual Property and Patents]
+++ covid-19_vaccines:lipid_nanoparticle [2022/11/24 19:45] (current)
liam [Intellectual Property and Patents]
@@ Line 13: / Line 13: @@
 ===== Intellectual Property and Patents =====
-The ownership and licensure of the LNP technology underlying the [[:mRNA]] [[:COVID-19 vaccines]] is controversial.
+The ownership and licensure of the LNP technology underlying the [[:mRNA]] [[:COVID-19 vaccines]] is controversial. See the below graphic from //Patent network analysis of mRNA-based vaccine candidates for COVID-19//:((Gaviria, M., & Kilic, B. (2021). //A network analysis of COVID-19 mRNA vaccine patents.// Nature Biotechnology, 39(5), 546–548. https://doi.org/10.1038/s41587-021-00912-9))
+{{:covid-19_vaccines:41587_2021_912_fig1_html_copy.jpg?600 |}}
+==== Patents ====
+The following patents are involved in the development of the LNP technology in question:
+  * 2201121 - //Bilayer stabilizing components and their use in forming programmable fusogenic liposomes//((Madden, T. D., Cullis, P. R., & Holland, J. W. (1994). //Bilayer stabilizing components and their use in forming programmable fusogenic liposomes// (Canadian Intellectual Property Office Patent No. 2201121). https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2201121/summary.html?type=number_search&tabs1Index=tabs1_1))
 ==== Legal Challenges ====
@@ Line 20: / Line 27: @@
 The suit alleges that Moderna had licensed Arbutus' LNP technology for its products, but not specifically for their [[:moderna_mrna-1273|mRNA-1273]] [[:COVID-19 vaccines|COVID-19 vaccine product]]. While the companies are seeking financial compensation, they insist they do not intend to halt or otherwise impede the distribution of the product. Moderna denied the allegations, claiming they had created their own proprietary lipid nanoparticle delivery technology for use in their [[:mRNA]] platform.